Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype
ConclusionsPredicting axillary response following NST with baseline18F-FDG PET/CT can be performed when focusing on breast cancer subtypes. The easily computed PET-parameter SUVmax can predict axillary response in HER2-positive and TN breast cancer. This study adds to the accumulating evidence that studies investigating the value of18F-FDG PET/CT in breast cancer should always take subtypes into account.
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | CT Scan | HER2 | Neoadjuvant Therapy | PET Scan | Radiology | Study